Merck & Co Inc.

2026. g. 19. aug. 23:41 UTC

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

2026. g. 17. aug. 19:36 UTC

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

2026. g. 15. aug. 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

2026. g. 14. aug. 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

2026. g. 13. aug. 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

2026. g. 12. aug. 19:56 UTC

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

2026. g. 11. aug. 19:36 UTC

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

2026. g. 10. aug. 19:36 UTC

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

2026. g. 7. aug. 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

2026. g. 6. aug. 23:01 UTC

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

2026. g. 5. aug. 19:43 UTC

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

2026. g. 4. aug. 23:26 UTC

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

2026. g. 3. aug. 20:03 UTC

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

2026. g. 31. jūl. 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

2026. g. 30. jūl. 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

2026. g. 29. jūl. 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

2026. g. 28. jūl. 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

2026. g. 27. jūl. 20:06 UTC

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

2026. g. 24. jūl. 18:56 UTC

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

2026. g. 22. jūl. 19:46 UTC

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

2026. g. 21. jūl. 19:56 UTC

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

2026. g. 20. jūl. 20:02 UTC

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.